| Excerpt | Reference |
|---|
| "AL amyloidosis is characterized by the pathologic deposition as fibrils of monoclonal light chains (i." | ( Davern, S; Murphy, CL; O'Neill, H; Solomon, A; Wall, JS; Weiss, DT, 2011) |
| "Tracheobronchial amyloidosis is a rare manifestation of the disease and has never been described with FDG PET/CT." | ( Galas, JL; Neuman, A; Ouvrier, MJ; Pop, G; Soussan, M; Weinmann, P, 2011) |
| "AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia." | ( Sanchorawala, V, 2014) |
| "AL amyloidosis is the most common cause of acquired amyloid polyneuropathy, manifesting with both sensorimotor and autonomic neuronal dysfunction." | ( Broski, SM; Dispenzieri, A; Howe, BM; Johnson, GB; Spinner, RJ, 2016) |
| "Systemic peripheral amyloidosis is a rare disease in which misfolded proteins deposit in various organs." | ( Kennel, SJ; McWilliams-Koeppen, HP; Richey, T; Stuckey, A; Wall, JS, 2016) |
| "AL amyloidosis is a rare plasma cell dyscrasia characterized by multi-organ involvement and poor prognosis." | ( Cao, XX; Feng, J; Huang, XF; Li, J; Shen, KN; Zhang, CL; Zhang, L; Zhou, DB, 2017) |
| "Primarye systemic AL amyloidosis is a rare hematologic disorder." | ( Baaj, ME; Doghmi, K; Eddou, H; Maaroufi, HE; Mikdame, M; Moudden, MK; Zinebi, A, 2017) |
| "Primary systemic amyloidosis is characterized by the deposition of insoluble monoclonal immunoglobulin light chains in various tissues and is usually associated with an underlying plasma cell dyscrasia." | ( Jurčić, V; Marko, PB; Trajber Horvat, A; Trčko, K, 2018) |
| "AL amyloidosis is an insidious and potentially fatal condition." | ( Audo, I; Augstburger, E; Sahel, JA, 2020) |
| "AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia." | ( Sanchorawala, V, 2020) |
| "The incidence of AL amyloidosis is approximately 12 cases per million persons per year and there is an estimated prevalence of 30 000 to 45 000 cases in the US and European Union." | ( Dispenzieri, A; Gertz, MA, 2020) |
| "Systemic AL amyloidosis is a protein-misfolding disorder that is characterized by the deposition of insoluble amyloid fibrils derived from kinetically unstable light chains." | ( Chakraborty, R; Lentzsch, S, 2020) |
| "Systemic AL amyloidosis is a disease wherein amyloid proteins derived from monoclonal immunoglobulin light chains produced by abnormal plasma cells are deposited in the tissues through the whole body and cause organ failure." | ( Fuchida, SI, 2021) |
| "AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia." | ( Boccadoro, M; Gertz, M; Hegenbart, U; Kastritis, E; Landau, H; Mollee, P; Palladini, G; Sanchorawala, V; Wechalekar, A, 2022) |
| "AL amyloidosis is a life-threatening disease characterized by the deposition of amyloidogenic immunoglobulin light chain secreted from clonal plasma cells." | ( Abe, Y; Caaveiro, JMM; Matsunaga, E; Takahashi, D; Ueda, T; Yamashita, T, 2022) |
| "Systemic AL amyloidosis is a rare protein misfolding disease that causes serious damage to different organs, especially the heart and kidneys." | ( Blair, HA, 2022) |
| "AL amyloidosis is associated with substantial costs and suboptimal outcomes, highlighting the need for new therapeutic approaches to prevent organ deterioration, and reduce disease burden." | ( Abonour, R; Ammann, E; Cote, S; D'Souza, A; Dispenzieri, A; Hoffman, J; Lam, A; Lee, C; Liedtke, M; Nair, S; Potluri, R; Tran, N; Wong, SW; Zonder, J, 2023) |
| "AL amyloidosis is a rare condition characterized by the overproduction of an unstable free light chain, protein misfolding and aggregation, and extracellular deposition that can progress to multiorgan involvement and failure." | ( Adler, ED; Ajmera, V; Asimakopoulos, F; Barman, P; Berumen, J; Bower, R; Brubaker, AL; Costello, C; Kearns, M; Khan, A; Kono, Y; Parekh, JR; Pretorius, V; Sanchez, R; Schnickel, GT; Shah, M; Silva Enciso, J; Taj, R; Tran, H; Urey, MA, 2023) |
| "Cardiac AL amyloidosis is a medical emergency causing rapid deterioration of cardiac function; however, it remains to be a diagnostic challenge especially when presenting with unusual symptoms and clinical findings." | ( Hatipoglu, S; Wechalekar, AD; Wechalekar, K, 2023) |
| Excerpt | Reference |
|---|
| "Fifty-three patients with systemic AL amyloidosis (those with malignancies were excluded) were treated in our hospital with HDM (15 patients), melphalan + prednisolone (MP) (17 patients), vincristine + adriamycin + dexamethasone (VAD) (11 patients), or supportive treatment (no chemotherapy, 10 patients)." | ( Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Sawa, N; Sumida, K; Suwabe, T; Takaichi, K; Takemoto, F; Taniguchi, S; Ubara, Y; Yamanouchi, M, 2011) |
| "To investigate the treatment of primary amyloidosis with high-dose melphalan and autologous hematopoietic stem cell transplantation to further examine the survival, hematologic response, and improvement of amyloid-related organ dysfunction." | ( Cen, XN; Dong, YJ; Li, Y; Liang, ZY; Liu, W; Ou, JP; Qiu, ZX; Ren, HY; Sun, YH; Wang, LH; Wang, MJ; Wang, WS; Xu, WL; Yin, Y, 2012) |
| "Treatment of primary amyloidosis with high-dose melphalan followed by autologous peripheral blood stem cell transplantation produced high efficacy." | ( Cen, XN; Dong, YJ; Li, Y; Liang, ZY; Liu, W; Ou, JP; Qiu, ZX; Ren, HY; Sun, YH; Wang, LH; Wang, MJ; Wang, WS; Xu, WL; Yin, Y, 2012) |
| "Patients with AL amyloidosis and low bone marrow plasma cell count generally undergo the harvest of hematopoietic cells from peripheral blood, followed by high-dose chemotherapy immediately after they are diagnosed." | ( Adam, Z; Cermáková, Z; Král, Z; Krejčí, M; Pour, L; Sčudla, V, 2013) |
| "Outcome and organ function of stage III AL amyloidosis without very elevated NT-proBNP and low SBP is improved by a very good hematologic response to chemotherapy." | ( Dimopoulos, MA; Foard, D; Foli, A; Gillmore, JD; Hawkins, PN; Hegenbart, U; Kastritis, E; Lane, T; Merlini, G; Milani, P; Palladini, G; Rannigan, L; Schonland, SO; Wechalekar, AD, 2013) |
| "Ten patients with primary systemic AL amyloidosis treated at our institute were evaluated." | ( Aoki, Y; Hayashi, T; Igarashi, T; Ikeda, H; Ishida, T; Maruyama, Y; Nojima, M; Shinomura, Y, 2014) |
| "A 77-year-old Korean man diagnosed with primary amyloidosis was started on melphalan/dexamethasone combination therapy." | ( Choi, BS; Chung, CH; Kim, J; Moon, DS; Moon, WR; Park, SG; Yoon, YM, 2015) |
| "The patients were newly diagnosed with AL amyloidosis with renal (100%), cardiac (72%), hepatic (19%) or nervous system (10%) involvement and underwent a median of 2 (1-6) cycles of BD treatment." | ( Chen, W; Huang, X; Liu, Z; Ren, G; Wang, Q, 2016) |
| "Patients with AL amyloidosis treated with HDM/SCT between 2011 and 2014 with severe hypoalbuminemia (SH), defined as serum albumin ⩽2 g/dL were studied retrospectively." | ( Brauneis, D; Lee, SY; Meehan, RS; Quillen, K; Sanchorawala, V; Seldin, DC; Shelton, A; Sloan, JM, 2016) |
| "Patients with AL amyloidosis who need second-line therapy after response to up-front treatment generally have a good outcome." | ( Basset, M; Foli, A; Merlini, G; Milani, P; Palladini, G; Perlini, S; Russo, F, 2018) |
| "In conclusion, GI perforation in AL amyloidosis is rare and mostly reported after treatment initiation." | ( Avivi, I; Cohen, Y; Duek, A; Gatt, ME; Leiba, M; Shaulov, A, 2018) |
| "Compared with AL amyloidosis, patients with AH amyloidosis exhibit a better prognosis and they may not need an aggressive treatment." | ( Ichimata, S; Kanno, H; Katoh, N; Kobayashi, M; Shimojo, H; Yazaki, M, 2018) |
| "All patients with AL amyloidosis treated with pomalidomide between 2009 and 2017 were included." | ( Gilmore, J; Hawkins, P; Lachmann, H; Mahmood, S; Manwani, R; Sachchithanantham, S; Sharpley, FA; Wechalekar, A; Whelan, C, 2018) |
| "We report a rare case of AL amyloidosis coincidence with psoriasis treated by ASCT." | ( Chen, W; Huang, X; Ren, G; Zuo, K, 2018) |
| "In appropriately selected patients with AL amyloidosis, autologous stem cell transplant (ASCT) is an established treatment modality with excellent outcomes and decreasing transplant related mortality (TRM) over time." | ( Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Gonsalves, WI; Hayman, SR; Hogan, WJ; Kapoor, P; Kourelis, TV; Kumar, SK; Lacy, MQ; Leung, N; Muchtar, E; Sidana, S; Sidiqi, MH; Warsame, R; Wolf, RC, 2019) |
| "Bortezomib is standard treatment in AL amyloidosis (AL), but is contraindicated in patients with significant neuropathy." | ( Cheesman, S; Gillmore, JD; Hawkins, PN; Kyriakou, C; Lachmann, HJ; Mahmood, S; Manwani, R; Popat, R; Rabin, N; Sachchithanantham, S; Shah, R; Sharpley, F; Smith, M; Wechalekar, AD; Worthington, S; Yong, K, 2019) |
| "In this study, 94 patients with AL amyloidosis (baseline BNP ≥150 pg/ml) had BNP measured at 6 months following treatment." | ( Doros, G; Lilleness, B; Ruberg, FL; Sanchorawala, V, 2020) |
| "Patients with AL amyloidosis and immunoglobulin deposition diseases (IDD) are vulnerable during the COVID-19 pandemic due to the immune compromise from the plasma cell disorder and therapy-related immune defects." | ( Bahlis, NJ; Duggan, P; Jimenez-Zepeda, VH; Lee, H; McCulloch, S; Neri, P; Tay, J, 2021) |
| "The goal of therapy in AL amyloidosis is to inhibit further production of the amyloidogenic light chains, thereby allowing organ recovery and improving survival." | ( Al Saleh, AS; Buadi, F; Dingli, D; Dispenzieri, A; Gertz, M; Gonsalves, W; Hayman, S; Hogan, W; Kourelis, T; Kumar, S; Lacy, M; Leung, N; Muchtar, E; Sidiqi, MH; Vaxman, I; Warsame, R, 2021) |
| "We conducted a retrospective study of AL amyloidosis patients treated with bortezomib to investigate the predictive value of a stringent dFLC response." | ( Cao, XX; Feng, J; Li, J; Miao, HL; Shen, KN; Wei, S; Zhang, CL; Zhang, L; Zhou, DB, 2021) |
| "Newly diagnosed patients with AL amyloidosis treated with ASCT or bortezomib between 2001 and 2018 were identified." | ( Cohen, O; Fontana, M; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Mahmood, S; Manwani, R; Martinez De Azcona Naharro, A; Petrie, A; Sachchithanantham, S; Sharpley, FA; Wechalekar, AD; Whelan, CJ, 2021) |
| "All patients seen at the National Amyloidosis Centre, UK, between February 2010 and August 2019 and treated with up-front bortezomib are included." | ( Cohen, OC; Foard, D; Fontana, M; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Law, S; Mahmood, S; Martinez-Naharro, A; Ravichandran, S; Sachchithanantham, S; Wechalekar, AD; Whelan, C, 2021) |
| "We review the management of AL amyloidosis, including factors that determine transplant eligibility, treatment options for transplant-ineligible patients, and treatment options for relapsed/refractory AL amyloidosis." | ( Abdallah, M; Sanchorawala, V, 2022) |
| "Strikingly, in mice bearing AL amyloidosis cell line xenografts, single agent treatment with the BCL-2 inhibitor ABT-199 (venetoclax) produces deeper remissions than bortezomib and triples median survival." | ( Blevins, F; Bradshaw, GA; Choiniere, J; Fraser, CS; Hata, AN; Kalocsay, M; Li, C; Miller, JW; Presser, A; Qin, X; Sanchorawala, V; Sarosiek, KA; Sarosiek, S; Spetz, JKE; Yu, S, 2022) |
| "We collected medical records of 302 AL amyloidosis patients and compared survival outcomes by predominant treatment strategy and at four time points: 1995-2003, 2004-2008, 2009-2013, and 2014-2018." | ( Choi, JO; Choi, JY; Jeon, ES; Kim, BJ; Kim, D; Kim, JS; Kim, K; Kim, SJ; Lee, JE; Min, JH; Yoon, SE, 2023) |
| "Herein we report a case of AL amyloidosis who was treated with HDM-ASCT, resulting in preserved cardiac function and resolution of proteinuria for more than 17 years after HDM-ASCT ensuing atrial fibrillation and complete atrioventricular block required management by catheter ablation and pacemaker implantation 10 years and 12 years after transplantation, respectively." | ( Iijima, T; Ikuma, D; Kono, K; Mizuno, H; Oba, Y; Ohashi, K; Sawa, N; Suwabe, T; Ubara, Y; Wake, A; Yamanouchi, M, 2023) |
| "In untreated systemic AL amyloidosis, Dara-Vd produces rapid and deep hematologic and organ responses." | ( Aras, MA; Arora, S; Chung, A; Kennedy, VE; Maringanti, SA; Martin, TG; Natsuhara, K; Shah, ND; Wolf, J; Wong, SW, 2023) |